Lesotho Set to Receive First Batch of Lenacapavir Vaccine to Strengthen HIV Prevention

Lesotho is set to receive the first batch of the Lenacapavir vaccine on Friday, with doses arriving at the National Drug Service Organisation (NDSO) in Mafeteng. Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) injection designed to prevent HIV infection for six months, administered twice a year. The introduction of this vaccine represents a major step in the country’s ongoing efforts to reduce HIV transmission and strengthen public health. Minister of Health Selibe Mochoboroane announced in the National Assembly that the first batch will be split into two shipments, with 3,840 doses in the first and 2,160 in the second. The vaccine’s arrival underscores Lesotho’s commitment to expanding preventive measures and supporting people at risk of HIV infection.

The Minister further disclosed that the second batch, consisting of 6,500 doses, is expected by the end of July, with additional doses scheduled for September and November. While the vaccine offers a six-month protection period, recipients will not be required to take the second dose if they feel they are no longer at risk. This approach allows individuals to make informed choices based on their personal risk factors while still benefiting from preventive protection. Health officials emphasize that access to Lenacapavir will complement existing HIV prevention strategies, including regular testing, condom use, and early treatment for those living with HIV. The phased rollout ensures that supply meets demand and provides sufficient coverage across priority populations.

Recent reports from the Ministry of Health show significant progress in combating HIV and AIDS in Lesotho. HIV infections have reportedly decreased by 83 percent, and AIDS-related deaths have been reduced by half. Additionally, 97 percent of Basotho are aware of their HIV status, and 97 percent of those diagnosed are receiving life-saving treatment. Of those on treatment, 99 percent are virally suppressed, demonstrating the effectiveness of the country’s treatment programs. The introduction of Lenacapavir is expected to build on these achievements by preventing new infections and reducing the burden on healthcare systems.

Lenacapavir offers a convenient option for individuals who may struggle with daily oral PrEP adherence. Its twice-yearly administration simplifies preventive care and increases the likelihood of consistent protection. Health authorities plan to target high-risk populations, including young adults, sex workers, and people in areas with high HIV prevalence, to maximize the vaccine’s impact. The integration of Lenacapavir into existing HIV prevention programs will be accompanied by awareness campaigns to educate communities on its use, benefits, and safety. By combining prevention, testing, and treatment, Lesotho aims to achieve sustained reductions in new infections and improve overall public health outcomes.

The arrival of Lenacapavir in Lesotho marks a critical milestone in the country’s fight against HIV/AIDS. With strong national commitment, ongoing public health efforts, and high levels of treatment coverage, the vaccine is expected to significantly contribute to reducing new HIV infections. Its introduction complements Lesotho’s broader strategy of prevention, early diagnosis, and treatment, reinforcing the country’s progress toward controlling the epidemic. As more doses arrive and coverage expands, Lenacapavir has the potential to strengthen HIV prevention, empower communities, and support the long-term goal of achieving an AIDS-free generation.